Castle Biosciences Aktie [WKN DE: A2PNH3 / ISIN: US14843C1053]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Castle Biosciences Inc Registered Shs

01.05.24		Ausblick: Castle Biosciences legt Quartalsergebnis vor (finanzen.net)
30.04.24		Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma (Businesswire)
17.04.24		Erste Schätzungen: Castle Biosciences legt Quartalsergebnis vor (finanzen.net)
11.04.24		Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024 (Businesswire)
10.04.24		Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations (Businesswire)
10.04.24		Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year (Businesswire)
04.04.24		Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer (Businesswire)
02.04.24		Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference (Businesswire)
25.03.24		Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year (Businesswire)
12.03.24		Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum (Businesswire)
08.03.24		Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting (Businesswire)
07.03.24		In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups (Businesswire)
28.02.24		Recap: Castle Biosciences Q4 Earnings (Benzinga)
28.02.24		Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results (Businesswire)
27.02.24		Earnings Preview For Castle Biosciences (Benzinga)
26.02.24		Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging (Businesswire)
07.02.24		Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024 (Businesswire)
14.01.24		Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii® (Businesswire)
09.01.24		Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report (Businesswire)
08.01.24		Castle Biosciences Expects FY23 Revenue To Exceed $210 Mln, Surpassing Previous Outlook (RTTNews)
20.12.23		Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
01.12.23		Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results (Businesswire)
14.11.23		Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting (Businesswire)
13.11.23		Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year (Businesswire)
08.11.23		Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder (Businesswire)
08.11.23		Castle Biosciences to Present at Upcoming Investor Conferences (Businesswire)
03.11.23		Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas (Businesswire)
02.11.23		Early Discovery Data Shows Ability of Castle Biosciences’ Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy (Businesswire)
01.11.23		Ausblick: Castle Biosciences stellt Zahlen zum jüngsten Quartal vor (finanzen.net)
24.10.23		Castle Biosciences to Present New Data on its TissueCypher® Barrett’s Esophagus Test at the 2023 American College of Gastroenterology Annual Scientific Meeting (Businesswire)
19.10.23		Castle Biosciences to Release Third Quarter 2023 Financial Results and Host Conference Call on Thursday, Nov. 2 (Businesswire)
18.10.23		New Data Highlights Clinical Utility and Performance of Castle Biosciences’ Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference® (Businesswire)
05.10.23		DecisionDx®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma (Businesswire)
02.10.23		Castle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett’s Esophagus (Businesswire)
25.09.23		Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma (Businesswire)
19.09.23		Castle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry (Businesswire)
14.09.23		TissueCypher® Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus (Businesswire)
12.09.23		Castle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory (Businesswire)
08.09.23		TissueCypher® Provides Clinically-Impactful Risk Stratification in Patients with Barrett’s Esophagus (Businesswire)
06.09.23		Castle Biosciences to Highlight Clinical Value of IDgenetix® Test at Psych Congress 2023 (Businesswire)
05.09.23		Castle Biosciences to Participate in Upcoming Investor Conferences (Businesswire)
07.08.23		New Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus (Businesswire)
01.08.23		Castle Biosciences to Present at the Canaccord Genuity 43rd Annual Growth Conference (Businesswire)
01.08.23		Ausblick: Castle Biosciences veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
19.07.23		Castle Biosciences to Release Second Quarter 2023 Financial Results and Host Conference Call on Wednesday, Aug. 2 (Businesswire)
18.07.23		Castle Biosciences to Host Second Annual Castle Cares Charity Walk (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Solana Kurs Prognose: – 10 Prozent in einer Woche – Jetzt schnell verkaufen?

Lufthansa-Aktie in Rot: JPMorgan warnt vor weiterem Kursrückgang bei Lufthansa - Hybridanleihe platziert

ATX-Papier voestalpine-Aktie: So viel Verlust hätte ein Investment in voestalpine von vor 10 Jahren bedeutet

DEUTZ-Aktie tiefer: DEUTZ unter den Bietern - Interesse an thyssenkrupps Marine Systems

Bitcoin fällt auf Niveau von Ende 2024 zurück - Kursverluste setzen sich fort

Pierer Mobility-Aktie knickt ein: KTM-Mutter Pierer Mobility setzt Hauptversammlung für Ende Januar an

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	11.01.2025 23:07
Kaufwert:	EUR
	Hinzufügen Speichern